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Detection of COPD in a high-risk population: 
should the diagnostic work-up include 
bronchodilator reversibility testing?
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Charlotte suppli Ulrik1,4
1Department of Pulmonary Medicine, 
hvidovre hospital, hvidovre; 2allergy 
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Copenhagen, Denmark
Background: Underdiagnosis of chronic obstructive pulmonary disease (COPD) is widespread. 
Early detection of COPD may improve the outcome by timely smoking cessation, a change in 
lifestyle, and treatment with an inhaled bronchodilator (BD). The objective of this study was to 
evaluate the diagnostic role of BD reversibility testing in early COPD case finding.
Methods: General practitioners (n=241) consecutively recruited subjects aged 35 years with 
relevant exposure (history of smoking, and/or occupational exposure) and at least one respira-
tory symptom. Information on age, smoking status, body mass index, dyspnea score (Medical 
Research Council scale), and spirometry was obtained. Individuals with airway obstruction 
(forced expiratory volume in one second [FEV
1
]/forced vital capacity [FVC] 0.70) underwent 
a BD test with an inhaled β
2
 agonist, which was considered positive if ΔFEV
1
 was 0.20 L 
and 12%. Asthma and COPD were, respectively, defined as an FEV
1
 increase 0.50 L and 
a post-BD FEV
1
/FVC 0.70.
Results: In total, 4,049 subjects (51% male) were included (mean age 58 years, body mass 
index 27, 32 pack-years of smoking). A significant BD response was found in 143 (15%) of the 
937 subjects (23%) with airway obstruction at screening spirometry. In 59% of these subjects, 
the post-BD FEV
1
/FVC remained 0.70. In 24% of the subjects with pre-BD airway obstruc-
tion, the post-BD FEV
1
/FVC ratio was within the reference range. In subjects with confirmed 
COPD, the mean increase in FEV
1
 following BD was 0.11 L±0.10 L. The subjects with COPD 
and a significant BD response were characterized by a higher prevalence of dyspnea (72% 
versus 57%, P=0.02) but less cough (55% versus 75%, P=0.001) when compared with COPD 
subjects without BD reversibility.
Conclusion: Administration of a BD in COPD case finding is important in order to determine 
the post-BD FEV
1
/FVC ratio. Exclusion of subjects with a significant BD response may result 
in underdiagnosis of COPD, and we question the need for the BD reversibility test in the diag-
nostic screening algorithm in early COPD case finding.
Keywords: chronic obstructive pulmonary disease, screening, reversibility, diagnosis, 
spirometry
Introduction
Chronic obstructive pulmonary disease (COPD) is a common disease, and it has been 
estimated that 23 million people in Europe are living with COPD stage II–IV and that 
17 million have stage I disease.1 The annual cost of COPD in Europe, including health 
care costs, has been estimated to be 141 billion Euros. Furthermore, the prevalence of 
the disease is predicted to increase until at least 2030.1
Secondary prevention is one way to address the increase in morbidity and health 
care expenses, and brings the importance of early detection of COPD into focus. 
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The symptoms of COPD are often acknowledged at a time 
when significant disease and loss of lung function has 
occurred and the consequence is therefore late diagnosis. 
Studies suggest that, on spirometric screening of high-risk 
populations, 19%–24% of the screened population will be 
diagnosed with COPD and a significant proportion will have 
mild to moderate airflow limitation.2–4
A subgroup analysis of the UPLIFT and TORCH 
studies, as well as a study by Tantucci et al5 show that the 
decline in lung function occurs faster in the earlier stages 
of the disease.5–7 Therefore, early diagnosis may provide 
the opportunity to prevent further deterioration in lung 
function, primarily by addressing exposure to inhaled 
noxious particles and gases, including smoking, physi-
cal activity, and possibly also to initiate pharmacological 
intervention.
Recommendations and diagnostic work-up for early case 
finding of COPD remain to be established. In some studies, 
a bronchodilator (BD) reversibility test (using a short-acting 
β
2
-agonist) has been performed as part of the diagnostic 
work-up in an attempt to distinguish between subjects with 
COPD and those with asthma.8–12 However, the value of 
the BD reversibility test as a diagnostic tool has been much 
debated because the presence of a significant BD response 
is an overlapping feature of COPD and asthma.1 In 2006, 
national recommendations for early detection of COPD in 
general practice in Denmark were implemented by the Danish 
National Board of Health. Based on these recommendations, 
a large study was conducted to evaluate the diagnostic yield, 
prevalence, and severity of COPD by following these recom-
mendations in a large cohort of individuals recruited through 
a representative sample of Danish general practitioners 
(GPs; the TOP GOLD study).2 As part of the study, data 
were obtained on spirometric findings and reversibility to a 
β
2
-agonist (and corticosteroids in some cases).
The objective of the present analysis of data from that 
study was to assess the diagnostic value of the BD revers-
ibility test in early case finding of COPD in a high-risk 
population identified in general practice.
Materials and methods
study design
GPs throughout Denmark were invited to take part in this 
study and the aim was to engage at least 200 GPs (5% of 
Danish GPs) in order to obtain a representative sample.2 Each 
of the participating GPs was expected to assess at least 20 
consecutive subjects who attended their practice and fulfilled 
the criteria for participation in the study (6-month study 
period). Subjects included had all study-related procedures 
performed in their own GP’s surgery.
Materials
Subjects were eligible for the study provided they fulfilled 
the inclusion criteria (age 35 years, smoker/ex-smoker or 
relevant occupational exposure, and at least one respiratory 
symptom [dyspnea, cough, wheeze, sputum, and/or recur-
rent chest infections]) and had no exclusion criteria (unable 
to perform spirometry, previous diagnosis of obstructive 
lung disease).
Methods
All participants filled in a questionnaire regarding age, sex, 
height, body weight, smoking status (including daily tobacco 
consumption and years of smoking), airway symptoms 
(including cough, dyspnea, wheezing, sputum, and recurrent 
lower airway infections), and severity of dyspnea (Medical 
Research Council scale).13 Spirometry was performed in 
accordance with the guidelines of the Danish Respiratory 
Society,14 and included at least three forced expiratory 
maneuvers (and at least two measurements of forced expira-
tory volume in one second [FEV
1
] and forced vital capacity 
[FVC], respectively, differing by less than 5%). European 
Community for Steel and Coal reference values for lung 
function was used.15
Diagnostic algorithm
Airway obstruction was defined as an FEV
1
/FVC ratio 0.70, 
in accordance with the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) strategy document.16 
All participants with a FEV
1
/FVC ratio 0.70 at screening 
spirometry (ie, pre-BD spirometry) had a BD reversibility test 
performed with 0.4 mg of inhaled salbutamol (or equivalent) 
followed by spirometry 15 minutes later; further details are 
given in Figure 1 (CONSORT diagram). Those with ΔFEV
1
 
of 0.200–0.500 L was further tested with a corticosteroid 
reversibility test performed with either inhaled budesonide 
1,600 µg daily (or equivalent) for 6 weeks or oral pred-
nisolone 37.5 mg daily for 10 days (further details in the 
diagnostic algorithm).17
Data handling and analysis
The results of the questionnaire and the spirometric data 
were recorded in a consolidated web-based database. Derived 
values were automatically calculated by the computer, 
including number of pack-years, body mass index (BMI), 
FEV
1
% predicted, FEV
1
/FVC, and COPD severity based 
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on FEV
1
% predicted. Statistical analyses were performed 
using Statistical Package for the Social Sciences version 
21.0 software (IBM Corporation, Armonk, NY, USA) with 
assistance from the Statistics Department, Clinical Research 
Centre, Hvidovre University Hospital, Denmark.
The analyses were limited to subjects with complete data. 
The data were tested for normality, and nonparametric tests 
for independent samples were used to analyze continuous data. 
Categorical data were analyzed using the Mann-Whitney U-test. 
In all the statistical analyses, a two-tailed P-value of 0.05 
was considered to be statistically significant. Mean values 
are reported with standard deviations. To test for outliers, the 
actual change in FEV
1
 following administration of BD was 
visualized by a dot plot, and data for individuals with a change 
of 1.0 L were excluded from the analyses. Negative values 
were excluded when calculating the mean FEV
1
 response to 
the reversibility test in order to describe the positive respond-
ers. Groups of interest were compared based on the presence 
of airway obstruction at screening spirometry, COPD, and BD 
reversibility. In the analyses, subjects were included in the 
“no COPD” group based on the following criteria: FEV
1
/FVC 
0.70 at screening spirometry or post-BD FEV
1
/FVC 0.70, 
a BD reversibility test with an increase in FEV
1
 0.500 L, or 
a positive corticosteroid reversibility test.
ethics statement
The present study was endorsed by the Danish College of 
General Practitioners. According to the European Federa-
tion of Pharmaceutical Industries and Associations code and 
the Danish Association of the Pharmaceutical Industry, the 
present study was a nondrug, noninterventional study, and 
approval from the scientific ethics committee and the Danish 
Medicines Agency were not mandatory, but they were given 
all relevant study information. The study was approved by 
the Danish Data Protection Agency.
Results
Characteristics of enrolled subjects
In total, 241 GPs (approximately 7% of all Danish GPs) 
participated in the study, and 4,049 subjects (51% male) 
with a mean age of 58 (range 35–91) years had complete 
data, so were included in the analyses. Fifty-nine percent of 
subjects were current smokers (48% males and 60% females), 
and 4% declared themselves as having never smoked. Mean 
estimated lifetime tobacco exposure among never, current, 
and former smokers was 37 (range 0–193) pack-years in men 
and 27 (range 0–168) pack-years in women.
Prevalence of airway obstruction 
at screening spirometry
In total, 937 (23%) of the 4,049 subjects had airway obstruc-
tion at screening, ie, an FEV
1
/FVC ratio 0.70 at the screen-
ing spirometry. The mean FEV
1
/FVC ratio was 0.61±0.08 in 
subjects with airway obstruction compared with 0.79±0.06 
in the remaining enrolled subjects. The mean FEV
1
 was 
2.0 L±0.7 L compared with 2.8 L±0.8 L in the subjects 
without airway obstruction and FEV
1
% predicted was 70% 
and 93%, respectively.
Respiratory symptom(s) and
FEV1/FVC <0.70
Reversibility test
<0.200 L or <12% >0.500 L
COPD
if FEV1/FVC <0.70
<0.200 L >0.200 L Asthma
0.200–0.500 L and >12%
Corticosteroid reversibility test
Figure 1 Flowchart describing the diagnostic algorithm used for participants with a screening spirometry revealing airflow obstruction (FEV1/FVC 0.70). 
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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Prevalence of COPD
Of the 4,049 subjects screened, 716 (18%) had a post-BD 
FEV
1
/FVC ratio 0.70. Twenty-three of these subjects had 
a post-BD increase in FEV
1
 0.500 L, and six subjects had 
a positive corticosteroid reversibility test. Thus, the criteria 
for diagnosis of COPD were met in 687 subjects (17%). Of 
the subjects with airway obstruction at screening spirometry, 
74% were diagnosed as having COPD and 2.5% as having 
asthma, whereas 23.5% had reversal of airway obstruction 
without fulfilling the criteria for asthma. Most subjects had 
mild to moderate disease (GOLD I, 31%; GOLD II, 53%) 
according to the GOLD classification of severity of airflow 
limitation16 (see Supplementary materials section). The mean 
FEV
1
 was 1.9 L in subjects diagnosed with COPD compared 
with 2.8 L in subjects who did not meet the criteria for COPD. 
Subjected diagnosed with COPD were on average 7 years 
older and had 10 pack-years more tobacco exposure compared 
with those without COPD (Table 1). Subjects who met the 
criteria for diagnosis of COPD also had a significantly higher 
prevalence of dyspnea, wheezing, sputum, and self-reported 
recurrent respiratory infections. The BMI was almost the 
same in the two groups (Table 1 and Figure 2).
Prevalence and characteristics of BD 
reversibility
The majority (88%) of the individuals had the BD reversibility 
test performed on the same day as the screening spirometry. Of 
the 937 subjects who had airway obstruction at screening spirom-
etry, a significant BD response was found in 143 (15%). Consid-
erable overlap was found between the presence of a significant 
BD response and the presence of airway obstruction (FEV
1
/FVC 
0.70, Figure 3). In 59% of the subjects who had a significant 
BD response, the post-BD ratio remained at 0.70. This group 
had a higher mean change in FVC (0.52 L±0.06 L) compared 
with the mean change in FEV
1
 (0.42 L±0.02 L). The mean 
pre-BD FEV
1
/FVC ratio was 0.56±0.009.
A total of 221 (24%) subjects with airway obstruction 
(FEV
1
/FVC ratio 0.70) at screening spirometry had no 
airway obstruction following administration of a BD. Of 
the 937 subjects tested for BD reversibility, 23 (3%) had an 
increase in FEV
1
 of 0.500 L in spite of a post-BD FEV
1
/
FVC ratio of 0.70.
In participants which met the criteria for diagnosis of 
COPD, the post-BD increase in FEV
1
 was 0.11 L±0.10 L and 
Table 1 Characteristics of enrolled subjects with a confirmed 
diagnosis of COPD (ie, post-bronchodilator FEV1/FVC 0.70) 
versus subjects not having COPD
COPD  
(n=687)
No COPDa  
(n=3,362)
P-value
sex, male 369 (54%) 1,688 (50%) 0.094
age 63 (10.5) 56 (11.8) 0.001
BMI 26 (5.1) 27 (5.1) 0.001
Pack-years 40 (23.2) 30 (21.9) 0.001
symptoms
Cough 501 (73%) 2,389 (71%) 0.324
Dyspnea 398 (58%) 1,554 (46%) 0.001
Wheezing 183 (27%) 559 (17%) 0.001
sputum 281 (41%) 963 (29%) 0.001
recurrent rTI 88 (13%) 28 (10%) 0.016
MrC 2 (0.8) 1.7 (0.7) 0.001
spirometry
FEV1 screening
b 1.9 (0.69) 2.8 (0.83) 0.001
FEV1% predicted
c 68 (19.4) 92 (18.2) 0.001
Notes: Data are given as the mean ± standard deviation or number of subjects (%). 
aSubjects with FEV1/FVC 0.70 or post-bronchodilator ΔFEV1 0.500 l; bFEV1 at 
initial screening spirometry; cFEV1 % predicted. 
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; 
MrC, Medical research Council dyspnea scale; rTI, respiratory tract infection.
Cough Dyspnea Wheezing Sputum Recurrent
respiratory
infections
COPD
No COPD
80%
70%
60%
50%
40%
30%
20%
10%
0%
Pe
rc
en
ta
ge
Figure 2 Prevalence of respiratory symptoms in individuals diagnosed with COPD 
compared with individuals not fulfilling the spirometric criteria for a diagnosis of 
COPD. 
Note: all enrolled subjects had more than one respiratory symptom.
Abbreviation: COPD, chronic obstructive pulmonary disease.
A
B
C
Figure 3 graphic representation of all subjects with airway obstructiona at 
screening spirometry (n=937) according to the presence of post-bronchodilator 
airway obstruction and/or BD reversibility.b 
Notes: (A) Subjects with post-BD airway obstruction, (B) subjects with a significant 
BD response, and (C) subjects with normal post-BD FEV1/FVC. 
aFEV1/FVC ratio 
0.70; bchange in FEV1 0.200 l and 12%. 
Abbreviations: BD, bronchodilator; FEV1, forced expiratory volume in one second; 
FVC, forced vital capacity.
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in 70% of the subjects the increase in FEV
1
 was 0.20 L. 
Overall, the mean post-BD increase in FEV
1
 of the sub-
jects with airway obstruction at screening spirometry was 
0.15±0.16 L. A total of 637 (68%) subjects had a positive BD 
response large enough to meet the cut-off criteria. A negative 
(ie, decline) change in FEV
1
 occurred in 157 (17%) of the 
tested subjects.
In 78 of the cases with a diagnosis of COPD, the severity 
of airflow limitation according to the GOLD classification 
was one step lower, and for one subject two steps lower, 
after the BD reversibility test. No difference was found 
between BD response and smoking status, pack-years, or 
age (Table 2).
Nine percent of subjects who met the criteria for diagno-
sis of COPD had a positive BD reversibility test, and these 
patients were characterized by a higher occurrence of dyspnea 
(72% versus 57%, P=0.024), whereas cough was reported 
less frequently (55% versus 75%, P=0.001) than in subjects 
without BD reversibility. There were no difference in BMI 
between the compared groups (Table 2).
Prevalence of reversibility 
to corticosteroids
A total of 128 subjects were tested further with corticoster-
oids due to an increase in FEV
1
 of 0.200–0.500 L on the BD 
reversibility test. Six subjects had a positive corticosteroid 
test (ie, a further increase in FEV
1
 of 0.200 L).
Discussion
The present study of early COPD case finding is by far the 
largest conducted study, with spirometric data from 4,049 
screened subjects at high risk of COPD; moreover, the inclu-
sion of 241 GPs across Denmark ensured a representative 
nationwide sample.
In the study, it was revealed that approximately one quar-
ter of the population at risk of COPD had airway obstruction 
when screened with spirometry. However, a quarter of these 
subjects with airway obstruction had an FEV
1
/FVC ratio 
within the reference range following administration of a BD, 
so did not meet the GOLD criteria for COPD. The post-BD 
ratio remained at 0.70 in the majority of the subjects who 
had a significant BD response.
The criteria for a diagnosis of COPD was met in 17% of 
the 4,049 included subjects, and in accordance with other 
studies of early COPD case finding, the severity of airflow 
obstruction was primarily mild to moderate (GOLD I, 31%; 
GOLD II, 53%).2–4 These results suggest that, in a defined 
population at risk of COPD who attend their GP for any 
reason, a substantial proportion can be diagnosed with the 
disease by an early case finding strategy.
The rationale for early case finding of COPD is supported 
by recent systematic reviews of the published literature 
concerning mild to moderate COPD, which favors early 
intervention.18,19 In line with this, BD therapy in relatively 
mild COPD, as assessed by spirometric criteria, can improve 
dyspnea and lung function.6,16,20
To our knowledge, the present study is the first to address 
the role of the BD reversibility test in early case finding of 
COPD as the primary objective; other studies of COPD case 
finding have mainly examined different screening tests, eg, 
simple spirometry (FEV
1
/FVC, FEV
1
/FEV
6
) or peak flow 
measurement and addressed the diagnostic yield.3,8–12,21–25
A prevalence of COPD in 17% of the screened population 
is lower than in other case finding studies, where a frequency 
of 20%–35% has been found.3,8–12,21–26 The proportion of 
individuals with COPD in a screened population at risk is 
dependent on both the criteria chosen to define “at risk”, as 
shown by Dirven et al10 and on applied diagnostic criteria 
for COPD. This was seen in the studies by Ulrik et al26 
 Vandevoorde et al25 Frith et al9 and Stratelis et al12 where the 
highest frequencies of COPD were found. The two first stud-
ies used the pre-BD FEV
1
/FVC to define airway obstruction, 
the second only included subjects aged older than 50 years, 
and the last one used the old 1995 criteria for COPD pub-
lished by the European Respiratory Society.27 Jordan et al23 
found a prevalence of COPD of only 5%, explained by 
their selection criteria (ever-smokers, age 30 years) and 
Table 2 Comparison of characteristics for subjects with a confirmed 
diagnosis of COPD (ie, post-bronchodilator FEV1/FVC 0.70) with 
and without bronchodilator reversibility
Reversibility 
(n=60)
No reversibility 
(n=627)
P-value
sex, male 35 (58%) 334 (52%) 0.452
age 63 (10.0) 63 (10.5) 0.407
BMI 26 (5.7) 26 (5.0) 0.531
Pack-years 42 (23.5) 40 (23.2) 0.380
symptoms
Cough 33 (55%) 468 (75%) 0.001
Dyspnea 43 (72%) 355 (57%) 0.024
Wheezing 16 (27%) 167 (27%) 0.996
sputum 25 (42%) 256 (41%) 0.900
recurrent rTI 10 (17%) 78 (12%) 0.349
MrC 2.2 (0.8) 2.0 (0.8) 0.152
spirometry
FEV1 screening
a 1.7 (0.6) 1.9 (0.7) 0.014
FEV1% predicted
b 58 (13.4) 68 (19.6) 0.001
Notes: Data are given as the mean (standard deviation) or number (%) of subjects; 
a positive reversibility test defined as ΔFEV1 0.200 L and 12% of pre-bronchodilator 
FEV1 level after administration of bronchodilator; 
aFEV1 at initial screening spirometry;
 
bFEV1 % predicted. 
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary 
disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; 
MrC, Medical research Council dyspnea scale; rTI, respiratory tract infection.
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a tight definition of COPD (airway obstruction and symptoms, 
and FEV
1
 80%). Except for the study by Jordan et al23 the 
present study had the lowest inclusion age (35 years), which 
is likely to explain the relatively low prevalence of COPD.
Subjects with COPD had a significant worse dyspnea 
grade and more wheezing, sputum, and recurrent respiratory 
infections compared with subjects without COPD. The dif-
ferences were modest, partly because the presence of at least 
one respiratory symptom was an inclusion criterion in the 
present study. The age was higher in the COPD group, which 
reflects the increasing prevalence in the elderly population. 
Overdiagnosis by use of a fixed FEV
1
/FVC ratio might in 
part have contributed to the difference.
In five further studies of COPD case finding (Frith et al,9 
Thorn et al,8 Stratelis et al,12 Canals et al,11 and Dirven et al10), 
a BD reversibility test was part of the diagnostic workup. BD 
reversibility in 9% of subjects with COPD as observed in 
the present study is high compared with some of the other 
studies.9,10 The comparison is complicated by differences in 
the definition of reversibility and perhaps also by the type and 
dose of BD. Frith et al9 and Canals et al11 had a definition of 
reversibility similar to that in the present study and reported 
an occurrence of 3% and 10%, respectively. In the studies 
with a different definition of reversibility, ie, Dirven et al10 
(ΔFEV
1
 12%) and Thorn et al8 (ΔFEV
1
 0.400 L), the 
occurrence of reversibility was 4.4% and 4%, respectively. 
The study reported by Stratelis et al12 did not specify the defi-
nition of reversibility. The occurrence of BD reversibility in 
the general COPD population has been described in several 
studies.28–31 A recent study of patients with COPD from the 
UPLIFT study found BD reversibility in 52% of patients 
using the same criteria for BD reversibility as those used in 
the present study.32
In 59% of the subjects in the present study who had a sig-
nificant BD response, the post-BD FEV
1
/FVC ratio remained 
at 0.70. This is explained by a larger increase in FVC rela-
tive to the change in FEV
1
 and for some participants a low 
pre-BD FEV
1
/FVC ratio. If the diagnosis of COPD is based 
on an algorithm that excludes all subjects with a significant 
BD response, there may be a substantial risk of underdiag-
nosis. The GOLD strategy document does not recommend 
use of a BD reversibility test in the diagnostic work-up of 
COPD.16 However, this is not the case for the diagnosis of 
asthma, with the Global Initiative for Asthma (GINA) strat-
egy document recommending a BD reversibility test if asthma 
is suspected.33 Still, it is recognized by the GINA guidelines 
that BD reversibility is a common feature of COPD.
The positive predictive value of the BD reversibility 
test is suspected to be low in COPD case finding where the 
population is selected based on risk factors for COPD. Thus, 
whether the BD reversibility test is necessary in early COPD 
case finding has to be considered. An alternative case finding 
model may be to administer a BD to all subjects identified 
with risk factors for COPD, and simply address whether the 
post-BD FEV
1
/FVC ratio is 0.70. The BD reversibility test 
can then be performed in post-screening assessment in cases 
where the suspicion of asthma justifies its use.
The diagnostic screening algorithm in early COPD case 
finding can select subjects with a high likelihood of COPD, 
but is not diagnostic in itself. The diagnosis of COPD should 
always be confirmed post-screening by careful individual 
clinical assessment.
Illustrated by recent publications on the overlap between 
asthma and COPD,33 the diagnostic differentiation between 
asthma and COPD is not a simple matter of reversibility of 
airway obstruction by a BD. This is emphasized by several 
studies in which a significant BD response was found in a 
considerable proportion of patients with COPD.30,34
A limitation of the present study is that the diagnosis of 
“confirmed” COPD is not based on thorough clinical assessment. 
Subjects may have had airway obstruction caused by a disease 
other than COPD, although the occurrence of non-COPD chronic 
airflow limitation is very low compared with the prevalence of 
COPD. The occurrence of asthma, which is regarded predomi-
nantly as a disease of children and younger subjects, would be 
expected to be low in the present study population based on the 
selection criteria (age 35 years and no prior obstructive lung 
disease). Due to the study design, which primarily relies on 
spirometric tests, it was not possible to differentiate COPD, late 
onset asthma, or asthma-COPD overlap syndrome.
The study does not account for temporal variation in indi-
vidual BD response or presence of airway obstruction, which 
has been demonstrated in studies with repeat testing.30,31,35 
There are no studies of the correlation between the case 
finding diagnosis of COPD and the final diagnosis after full 
clinical assessment.
In conclusion, a substantial proportion of subjects with 
pre-BD airway obstruction did not have COPD according 
to GOLD spirometric criteria based on their post-BD FEV
1
/
FVC ratio. Underdiagnosis of COPD may be a consequence if 
subjects are excluded based on a significant response in FEV
1
 
on the BD reversibility test. We question whether the BD 
reversibility test is a necessary part of the algorithm for the 
initial diagnostic screening in early COPD case finding.
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Supplementary material
Table S1 List of definitions
Definitions
airway obstruction FEV1/FVC ratio 0.70
BD reversibility test ERS/ATS recommendations: ”Significant” BD response was defined as an increase in FEV1  
of minimum 0.200 L and 12% of pre-BD FEV1 after administration of a short-acting β2 agonist30
Corticosteroid reversibility test six weeks of treatment with inhaled corticosteroid or 14 days of oral steroid followed  
by repeat spirometry. An increase in FEV1 of 0.200 l was considered a positive test
COPD Spirometric defined according to GOLD recommendations 2014: Post-BD FEV1/FVC ratio 0.70
16
gOlD severity of airway obstruction FEV1 % predicted:
gOlD 1: mild 80%
gOlD 2: moderate 50% FEV1 80%
gOlD 3: severe 30% FEV1 50%
gOlD 4: very severe 30%
asthma Increase in FEV1 0.500 l at the BD reversibility test or 0.200–0.500 l with additional 0.200 l 
increase on the corticosteroid reversibility test
Abbreviations: ATS, American Thoracic Society; BD, bronchodilator; COPD, chronic obstructive pulmonary disease; ERS, European Respiratory Society; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease.
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